Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effectiveness of Olanzapine for Patients with Schizophrenia

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the treatment of psychosis, a mental health condition that affects how a person thinks, feels, and behaves. The treatment being studied is a medication called olanzapine, which is taken as a film-coated tablet. The purpose of the study is to understand how genetic and epigenetic factors, which are variations in genes and changes in gene activity, affect the response to olanzapine treatment in patients with psychosis.

Participants in the study will be patients diagnosed with schizophrenia or schizoaffective disorders, which are specific types of psychosis. The study will look at the frequency of certain gene variations, known as polymorphisms, in genes like CYP1A2, MDR1, 5HT2A, 5HT2C, HDAC3, and HDAC4. These genes may influence how patients respond to olanzapine. The study will also assess other factors such as the rate of treatment response, which is measured by a reduction in symptoms, and any side effects experienced during the treatment.

Throughout the study, participants will be monitored for changes in their symptoms and any side effects from the medication. The study will also track how long it takes for participants to show a response to the treatment. This research aims to provide a better understanding of how olanzapine works in treating psychosis and how individual genetic differences can affect treatment outcomes.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be asked to provide your informed consent. This means you agree to participate and understand what the study involves.

    You will need to confirm that you meet the eligibility criteria, such as being between 18 and 60 years old and having a diagnosis of schizophrenia or schizoaffective disorder.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to establish a baseline for your condition. This may include various tests and questionnaires to evaluate your current health status and symptoms.

  3. Step 3

    Medication administration

    You will begin or continue treatment with olanzapine, which is taken orally. The dosage and frequency will be determined by the study team based on your individual needs.

    The duration of the medication administration will be specified by the study protocol, and you will be informed of any changes during the trial.

  4. Step 4

    Regular monitoring

    Throughout the trial, you will have regular check-ups to monitor your response to the treatment. This includes assessing any changes in your symptoms and overall health.

    You may be asked to complete questionnaires or undergo tests to evaluate the effectiveness of the treatment and any side effects.

  5. Step 5

    Genetic and epigenetic testing

    As part of the study, tests will be conducted to analyze specific genes and their variations, which may affect your response to the treatment.

    These tests aim to understand how genetic factors influence the effectiveness and safety of olanzapine in treating psychosis.

  6. Step 6

    Evaluation of treatment response

    Your response to the treatment will be evaluated using a scale called PANSS, which measures the severity of symptoms. A reduction in your score indicates improvement.

    The study will track how quickly you respond to the treatment and whether you achieve remission, which means a significant reduction in symptoms.

  7. Step 7

    Completion of the study

    At the end of the study, a final assessment will be conducted to evaluate your overall progress and any changes in your condition.

    You will be informed about the results of the study and any follow-up actions that may be necessary.

Who can join the trial?

5 criteria

  • Age between 18 and 60 years old
  • Diagnosed with schizophrenia or schizoaffective disorders according to the ICD-10 classification system
  • Currently receiving treatment with olanzapine or planning to start treatment with olanzapine
  • Willing to participate and have given informed consent
  • Women who can have children must use at least one effective method of birth control

Who cannot join the trial?

1 criterion

  • Patients with a history of psychoses cannot participate. Psychoses are mental health conditions that affect how a person thinks, feels, and behaves, often causing a loss of contact with reality.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Olanzapine is a medication used to treat symptoms of schizophrenia and bipolar disorder. It helps to balance certain chemicals in the brain, which can improve mood, thoughts, and behavior. In this clinical trial, olanzapine is being studied to see how genetic and epigenetic factors might affect how well it works for different people. The goal is to understand if certain genetic traits can influence the effectiveness of olanzapine in treating psychosis.

What is already known about the treatment

Olanzapine – Olanzapine is administered orally in the form of tablets and is used to treat psychosis, particularly in conditions like schizophrenia. It is currently well-established in medical practice and literature as an effective antipsychotic medication. The main therapeutic indication for olanzapine is the management of symptoms associated with psychotic disorders. At the molecular level, olanzapine works by blocking certain receptors in the brain, such as dopamine and serotonin receptors, which helps to balance neurotransmitters and reduce symptoms of psychosis. It is classified pharmacologically as an atypical antipsychotic.

Investigated diseases

Schizophrenia – Schizophrenia is a chronic mental disorder characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions. It often manifests through symptoms such as hallucinations, delusions, disorganized thinking, and significant social or occupational dysfunction. The progression of schizophrenia can vary, with some individuals experiencing episodes of acute symptoms followed by periods of remission, while others may have a more continuous course. Over time, cognitive functions such as memory, attention, and problem-solving may decline. The disorder typically emerges in late adolescence or early adulthood and can affect various aspects of daily life. The exact cause is unknown, but it is believed to involve a combination of genetic, brain chemistry, and environmental factors.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-502902-33-00Protocol codeSEOTP-2022Estimated enrolment200 patientsSponsorMasarykova Univerzita

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).